Objective: to evaluate the effect of the direct antiviral agents (DAAs) which are recently involved in 
treatment of hepatitis C virus (HCV) patients on the cardiac function. Patients and Methods: The 
study conducted on one hundred subjects with hepatitis C virus (HCV) and treated with doses of 
sofosbuvir (SOF) plus daclatasvir (DCV) only or in addition to weight-based ribavirin (RBV) for 12 
weeks. Level of human plasma B type naturetic peptide (BNP), and left ventricular ejection fraction 
(LVEF) measured by echocardiography were evaluated to all subjects included before starting 
treatment and at the sixth week and after the twelfth week of the treatment. Results: There were 
significant differences in levels of BNP and LVEF measurements through different times compared.
Conclusion: the patients included in the study with affected LVEF did not have heart failure 
symptoms. Statistically significant differences between parameters measured remained within the 
normal range.